Long-term influence of chemotherapy on steatosis-associated advanced hepatic fibrosis

Medical Oncology

Volumn 31, Issue 6, 2014, Pages

  Reddy, Srinevas K ^a,b   Reilly, Colleen ^a   Zhan, Min ^a   Mindikoglu, Ayse L ^a   Jiang, Yixing ^a   Lane, Barton F ^a   Alexander, H Richard ^a   Culpepper, William J ^a,b   El Kamary, Samer S ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Chemotherapy; Hepatic fibrosis; Nonalcoholic fatty liver disease; Steatohepatitis

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; IPILIMUMAB; IRINOTECAN; PANITUMUMAB; SORAFENIB; TRASTUZUMAB; ANTINEOPLASTIC AGENT; CAMPTOTHECIN;

ADULT; ARTICLE; CHEMOTHERAPY; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; FATTY LIVER; FEMALE; HUMAN; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREDICTIVE VALUE; PRIORITY JOURNAL; TREATMENT DURATION; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; COHORT ANALYSIS; COMPLICATION; MULTIVARIATE ANALYSIS; PROBABILITY; RETROSPECTIVE STUDY; RISK FACTOR;

ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; COHORT STUDIES; FATTY LIVER; FEMALE; FLUOROURACIL; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROBABILITY; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84905498998     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0971-y     Document Type: Article

References (56)

1. Vauthey JN, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal liver metastases. J Clin Oncol. 2006;24:2065-72. (Pubitemid 46622116)
2. Pawlik TM, Olino K, Gleisner AL, et al. Preoperative chemotherapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome. J Gastrointest Surg. 2007;11:860-8.
3. Wolf PS, Park JO, Bao F, et al. Preoperative chemotherapy and the risk of hepatotoxicity and morbidity after liver resection for metastatic colorectal cancer: a single institution experience. J Am Coll Surg. 2013;216:41-9.
4. Rubbia-Brandt L, Audard V, Sartoretti P, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol. 2004;15:460-6. (Pubitemid 38444550)
5. Peppercorn PD, Reznek RH, Wilson P, et al. Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer. Br J Cancer. 1998;77:2008-11. (Pubitemid 28254648)
6. Sorensen P, Edal AL, Madsen EL, et al. Reversible hepatic steatosis in patients treated with interferon alfa-2a and 5-fluorouracil. Cancer. 1995;15:2592-6.
7. Moertel CG, Fleming TR, Macdonald JS, et al. Hepatic toxicity associated with fluorouracil plus levamisole adjuvant therapy. J Clin Oncol. 1993;11:2386-90. (Pubitemid 23353968)
8. Morling JR, Fallowfield JA, Guha IN, et al. Using non-invasive biomarkers to identify hepatic fibrosis in people with type 2 diabetes mellitus: the Edinburgh type 2 diabetes study. J Hepatol. 2014;60:384-91.
9. Sumida Y, Yoneda M, Hyogo H, et al. Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population. BMC Gastroenterol. 2012;12:2.
10. Goldberg JW, Lidsky MD. Cyclophosphamide associated hepatotoxicity. South Med J. 1985;78:222-3.
11. Robinson K, Lambiase L, Li J, et al. Fatal cholestatic liver failure associated with gemcitabine therapy. Dig Dis Sci. 2003;48: 1804-8. (Pubitemid 37174737)
12. Aviles A, Herrera J, Ramos E, et al. Hepatic injury during doxorubicin therapy. Arch Pathol Lab Med. 1084;108:912-3.
13. Field KM, Dow C, Michael M. Part I: Liver function in oncology: biochemistry and beyond. Lancet Oncol. 2008;9:1092-101.
14. Hill JM, Loeb E, MacLellan A, et al. Clinical studies of platinum coordination compounds in the treatment of various malignant diseases. Cancer Chemother Rep. 1975;59:647-59.
15. Tran A, Housset C, Boboc B, et al. Etoposide (VP 16-213) induced hepatitis. Report of three cases following standard-dose treatments. J Hepatol. 1991;12:36-9.
16. Saif MW, Shahrokni A, Cornfield D. Gemcitabine-induced liver fibrosis in a patient with pancreatic cancer. JOP. 2007;8:460-7. (Pubitemid 47263686)
17. Huizing MT, Misser VH, Pieters RC, et al. Taxanes: a new class of antitumor agents. Cancer Invest. 1995;13:381-404.
18. Creemers GJ, Lund B, Verweij J. Topoisomerase I inhibitors: topotecan and irinotecan. Cancer Treat Rev. 1994;20:73-96.
19. King PD, Perry MC. Hepatotoxicity of chemotherapy. Oncologist. 2001;6:162-76. (Pubitemid 32323455)
20. Johnson DH, Greco FA, Wolff SN. Etoposide induced hepatic injury: a potential complication of high-dose therapy. Cancer Treat Rep. 1983;67:1023-4. (Pubitemid 14208705)
21. Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy. Gastroenterology. 2011;140:124-31.
22. Armstrong MJ, Houlihan DD, Bentham L, et al. Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort. J Hepatol. 2012;56:234-40.
23. Younossi ZM, Stepanova M, Afendy M, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1998 to 2008. Clin Gastroenterol Hepatol. 2011;9:524-30.
24. Krawczyk M, Bonfrate L, Portincasa P. Nonalcoholic fatty liver disease. Best Pract Res Clin Gastroenterol. 2010;24:695-708.
25. Levene AP, Goldin RD. The epidemiology, pathogenesis, and histopathology of fatty liver disease. Histopathology. 2012;61: 141-52.
26. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology. 1998;114:842-5.
27. Bohinc BN, Diehl AM. Mechanisms of disease progression in NASH: new paradigms. Clin Liver Dis. 2012;16:549-65.
28. Chun YS, Laurent A, Maru D, et al. Management of chemo-therapy- associated hepatotoxicity in colorectal liver metastases. Lancet Oncol. 2009;10:278-86.
29. Reddy SK, Marsh JW, Varley PR, et al. Underlying steatohepatitis, but not simple steatosis, increases morbidity after liver resection: a case-control study. Hepatology. 2012;56:2221-30.
30. Dyson JK, McPherson S, Anstee QM. Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification. J Clin Pathol. doi: 10.1136/jclinpath-2013-201620.
31. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142:1592-609.
32. Sanyal AJ, Brunt EM, Kleiner DE, et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology. 2011; 54:344-53.
33. Eckel RH, Alberti KGMM, Grundy SM, et al. The metabolic syndrome. Lancet. 2010;375:181-3.
34. Ascha MS, Hanounch IA, Lopez R, et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology. 2010;51:1972-8.
35. Reddy SK, Reilly C, Twaddell WS, et al. Low probability of hepatic fibrosis from noninvasive risk panels accurately excludes advanced fibrosis due to nonalcoholic fatty liver disease among hospitalized patients. World J Gastroenterol 2014; manuscript submitted.
36. McPherson S, Steward SF, Hendeson E, et al. Simple non-invasive fibrosis scoring systems can reliably excluded advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut. 2010;59:1265-9.
37. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38:518-26. (Pubitemid 36919874)
38. Petersen JR, Stevenson HL, Kasturi KS, et al. Evaluation of the aspartate aminotransferase/platelet ratio index and enhanced liver fibrosis tests to detect significant fibrosis due to chronic hepatitis C. J Clin Gastroenterol 2013 Sep 16 [epub].
39. Celikbilek M, Dogan S, Gursoy S, et al. Noninvasive assessment of liver damage in chronic hepatitis B. World J Hepatol. 2013; 5:439-45.
40. Loaeza-del-Castillo A, Paz-Pineda F, et al. AST to platelet ratio index (APRI) for the noninvasive evaluation of liver fibrosis. Ann Hepatol. 2008;7:350-7.
41. Palmeri ML, Wang MH, Rouze NC, et al. Noninvasive evaluation of hepatic fibrosis using acoustic radiation force-based shear stiffness in patients with nonalcoholic fatty liver disease. J Hepatol. 2011;55:666-72.
42. Kruger JC, Daniels CR, Kidd M, et al. APRI: a simple bedside marker for advanced fibrosis that can avoid liver biopsy in patients with NAFLD/NASH. S Afr Med J. 2011;101:477-80.
43. Dyson JK, McPherson S, Anstee QM. Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification. J Clin Pathol. 2013;66:1033-45.
44. Nakahara T, Hyogo H, Yoneda M, et al. Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients. J Gastroenterol 2013 Nov 26 [epub].
45. Gunneson TJ, Menon KV, Wiesner RH, et al. Ultrasound-assisted percutaneous liver biopsy performed by a physician assistant. Am J Gastroenterol. 2002;97:1472-5. (Pubitemid 34664795)
46. Szymczak A, Simon K, Inglot M, et al. Safety and effectiveness of blind percutaneous liver biopsy: analysis of 1412 procedures. Hepat Mon. 2012;12:32-7.
47. Behrens G, Ferral H. Transjugular liver biopsy. Semin Intervent Radiol. 2012;29:111-7.
48. Mueller M, Kratzer W, Oeztuerk S, et al. Percutaneous ultrasonographically guided liver punctures: an analysis of 1961 patients over a period of ten years. BMC Gastroenterol. 2012;12:173.
49. Foreman MG, Mannino DM, Moss M. Cirrhosis as a risk factor for sepsis and death: analysis of the National Hospital Discharge Survey. Chest. 2003;124:1016-20. (Pubitemid 37123324)
50. Pavon A, Binquet C, Kara F, et al. Profile of the risk of death after septic shock in the present era: an epidemiological study. Crit Care Med 2013; Aug 10 [epub].
51. Akiyama T, Chikuda H, Yasunaga H, et al. Incidence and risk factors for mortality of vertebral osteomyelitis: a retrospective analysis using the Japanese diagnosis procedure combination database. BMJ Open. 2013;25:3.
52. Al-Hasan MN, Lahr BD, Eckel-Passow JE, et al. Predictive scoring model of mortality in Gram-negative bloodstream infection. Clin Microbiol Infect 2012; Nov 8 doi: 10.1111/1469- 0691.12085 [epub].
53. Kang CI, Song JH, Chung DR, et al. Liver cirrhosis as a risk factor for mortality in a national cohort of patients with bacteremia. J Infect. 2011;63:336-43.
54. Field KM, Micheal M. Part II: Liver function in oncology: towards safer chemotherapy use. Lancet Oncol. 2008;9:1181-90.
55. Schwenzer NF, Springer F, Schraml C, et al. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol. 2009;51:433-45.
56. Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002;123:745-50. (Pubitemid 34977081)